Total amount: € 0,00
Colasanti P. 1, Tirri E. 2, Cordedda M. 1, Maione F. 1, Spanò G. 1, Zanchini R. 1, Mozzillo R. 1
1 Presidio Ospedaliero S. Gennaro, ASL Napoli 1 Centro, UOSD di Dermatologia, Napoli, Italia;
2 Presidio Ospedaliero S. Giovanni Bosco, Napoli ASL Napoli 1 Centro, UOSD di Reumatologia, Napoli, Italia
The occurrence of psoriasis in patients treated with tumor necrosis factor-alpha (TNF-α) is defined “paradoxical effect” and is characterized by the development of de novo psoriasis induced by the use of a drug which is normally utilized to treat skin disease itself. The authors describe two cases of de novo psoriasis in female patients affected by rheumatoid arthritis treated with certolizumab pegol (Cimzia®), a recombinant humanized antibody Fab fragment antibody directed against TNF-α conjugated with propylene glycol. In both cases personal or familiar history was negative for psoriasis. It is important for clinicians to be aware of this possible drug effect, especially considering the increasingly widespread use of these drugs.